The global Nanoparticles - Metal & Metal Oxides Market in
healthcare is anticipated to reach USD 80.74 billion by 2025, according to a
new report by Grand View Research, Inc. Several nanotechnologies based
medicines have been put forward for approval by the FDA which is anticipated to
propel growth.
Success of nanomedicine has prompted the development of enhanced
nanomaterials for clinical applications with particular emphasis in therapy and
diagnostics. This has resulted into the significant production of metal oxide
particles that hold potential utility in human medicine.
Remarkable evolution has been made in nanoparticle based
medicines for theranostic applications in disease management. Diverse metals
have been used for development of medicines with a promise to optimize the
efficacy of nanomedicines and to improve the current standard of medical and
clinical practices.
These particles are recognized to have major applications in
drug delivery, diagnostic products, biomarker discovery, and product packaging.
Widespread application spectrum of these particles in maintaining human health
is expected to dramatically impact the progress of this market in the coming
years.
Moreover, metal oxides are observed to have significant role in
cancer treatment. Nanoparticle-augmented systems enable high-concentration
targeted drug delivery to cancer cells, which in turn, is expected to enhance
the usage rate of metal nanoparticles for cancer treatment. Development of drug
delivery strategies using nanoparticle approaches are expected to bring about
changes effective for cancer treatment.
However, prolonged exposure of nanoparticles adversely affects
the human health as well environment thereby restraining their adoption rate.
These products are involved in autophagy, oxidative stress, lysosome
dysfunction, and the activation of certain signaling pathways, thereby
exhibiting toxicity for human health.
Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/nanoparticles-metal-oxides-in-healthcare-market
http://www.grandviewresearch.com/industry-analysis/nanoparticles-metal-oxides-in-healthcare-market
Further key findings from the report suggest:
- Presence
of untapped potential in alumina and alumina oxide particles is
anticipated to create immense opportunities
- Aluminum
oxide in combination with polymeric membranes is studied for enhancement
of drug delivery owing to its high porosity property displayed in the
membranes
- This
enhanced efficacy of the membrane performance by the addition of alumina
nanoparticles to polymeric membranes is projected to increase its adoption
- Approval
of various nanoparticle composition and surface properties for clinical
diagnostics and treatment of viral infections is anticipated drive market
demand
- In-vivo imaging
dominated the market with respect to revenue share
- Use
of antibody conjugated to Au nanorods Raman spectrum with polarized,
sharpened, and enhanced results can be attributed for larger revenue share
- Oncology
dominated over a decade and is projected to sustain its share over the
forecast period.
- Rising
incidence of cancer and other chronic multi-drug resistant diseases
pronounces the demand for these particles.
- Aforementioned
factor is anticipated to drive targeted delivery with fastest YoY growth
- Asia
Pacific is projected to showcase lucrative progress in the coming years
- Key
countries in the region are working to enhance the patient’s reach to
nanotechnology-based solutions
- Moreover,
continuous support from the government bodies pertaining to initiation of
new projects is expected to play crucial role for projected CAGR
- Key
players contributing in this market are Pfizer Inc., Brigham Women's
Hospital (BWH), Immunolight LLC, nanoComposix, Nanobiotix, Nanospectra
Biosciences, Inc, Merck KGaA, and AstraZeneca
- These
participants are investing in development of the product portfolio that
can target the chronic disorders
- Arrowhead
Pharmaceuticals, Cytimmune Sciences, Inc, Nanobiotix, Celgene Corporation,
Siteman Center of Cancer Nanotechnology Excellence (Washington University
CCNE), and BIND Biosciences are few companies that have products in the
pipeline phase
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment